Xenon Pharmaceuticals (XENE) Misses Q1 EPS by 5c

Xenon Pharmaceuticals (NASDAQ: XENE) reported Q1 EPS of ($0.43), $0.05 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $300 thousand.

For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.

You May Also Be Interested In

• United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
• Novartis shares plunge 10% as failed drug trial clouds growth outlook
• GE Aerospace to buy CPP for $11.75 billion in castings deal